HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The effects of intraganglionic injection of calcium/calmodulin-dependent protein kinase II inhibitors on pain-related behavior in diabetic neuropathy.

Abstract
Calcium/calmodulin-dependent protein kinase II (CaMKII) has been implicated in the transmission of nociceptive input in diabetic neuropathy. The aim of this study was to test whether intraganglionic (i.g.) injection of CaMKII inhibitors may alleviate pain-related behavior in diabetic rats. Diabetes was induced in Sprague-Dawley rats using 55 mg/kg streptozotocin intraperitoneally. Two weeks after diabetes induction, CaMKII inhibitors myristoil-AIP and KN93 were injected directly into the right L5 dorsal root ganglion (DRG). Behavioral testing with mechanical and thermal stimuli was performed before induction of diabetes, the day preceding the injection, as well as 2 and 24h after the i.g. injection. The expression of total CaMKII and its alpha isoform in DRG neurons was analyzed using immunohistochemistry. CaMKII inhibitors attenuated pain-related behavior in a modality-specific fashion. Attenuation of nociceptive behavior was accompanied with a corresponding decrease of CaMKII alpha expression in DRG neurons on the side of injection. A significant decrease of CaMKII alpha expression was seen in small- and medium-sized neurons. In conclusion, our study provides evidence that CaMKII inhibitors are potential pharmacological agents that should be further explored for treatment of diabetic neuropathy symptoms.
AuthorsA Jelicic Kadic, M Boric, S Kostic, D Sapunar, L Puljak
JournalNeuroscience (Neuroscience) Vol. 256 Pg. 302-8 (Jan 03 2014) ISSN: 1873-7544 [Electronic] United States
PMID24161721 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2013 IBRO. Published by Elsevier Ltd. All rights reserved.
Chemical References
  • Antibiotics, Antineoplastic
  • Benzylamines
  • Enzyme Inhibitors
  • Sulfonamides
  • KN 93
  • Streptozocin
  • Calcium-Calmodulin-Dependent Protein Kinase Type 2
Topics
  • Animals
  • Antibiotics, Antineoplastic (toxicity)
  • Benzylamines (therapeutic use)
  • Calcium-Calmodulin-Dependent Protein Kinase Type 2 (metabolism)
  • Diabetic Neuropathies (chemically induced, drug therapy)
  • Disease Models, Animal
  • Enzyme Inhibitors (therapeutic use)
  • Functional Laterality
  • Ganglia, Spinal (drug effects, physiology)
  • Male
  • Pain Threshold (drug effects)
  • Rats
  • Rats, Sprague-Dawley
  • Streptozocin (toxicity)
  • Sulfonamides (therapeutic use)
  • Time Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: